title: [The German Society of Pediatric Oncology Cooperative Ewing Sarcoma Studies CESS 81/86: report after 6 1/2 years].
abstract: The GPO Cooperative Ewing's Sarcoma Study (CESS 81 with 10 months four-drug combination chemotherapy (vincristine, actinomycin D, cyclophosphamide, and adriamycin = VACA) and local control with surgery and/or radiation, following week 18, resulted in a Kaplan-Meier estimated disease-free survival of 51% after 6 1/2 years (51/93 patients disease-free). Tumor volume and histological response to primary chemotherapy were identified as most significant prognostic factors. As a consequence, the CESS 86 regimen was stratified according to risk of relapse. Standard risk patients (extremity tumors less than 100 ml tumor volume) were continued on VACA chemotherapy. In high risk patients (extremity tumors greater than 100 ml tumor volume, central tumors), cyclophosphamide in conventional dose (1200 mg/m2/course) was replaced by high doses of ifosfamide (6 g/m2/course) with mesna uroprotection (VAIA). Local control was obtained following week 9. Patients with radiation were randomised for conventional fractionation or accelerated split-course hyperfractionation. The study was piloted from February to December 1985: 27/37 patients were disease-free on October 1, 1987. The ongoing trial was started on January 1, 1986. On October 1, 1987. 63/66 patients were disease-free. In patients with large primaries, according to Kaplan-Meier life-table analysis, the disease-free survival was significantly better in patients receiving VAIA chemotherapy, compared to the previous VACA regimen. The toxicity of both combination chemotherapy regimens was comparable.
authors.affiliation: Universitäts-kinderkliniken Düsseldorf.
authors.forename: H
authors.initials: H
authors.lastname: Jürgens
authors.forename: V
authors.initials: V
authors.lastname: Bier
authors.forename: J
authors.initials: J
authors.lastname: Dunst
authors.forename: D
authors.initials: D
authors.lastname: Harms
authors.forename: A
authors.initials: A
authors.lastname: Jobke
authors.forename: R
authors.initials: R
authors.lastname: Kotz
authors.forename: J
authors.initials: J
authors.lastname: Kühl
authors.forename: S
authors.initials: S
authors.lastname: Müller-Weihrich
authors.forename: J
authors.initials: J
authors.lastname: Ritter
authors.forename: M
authors.initials: M
authors.lastname: Salzer-Kuntschik
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D010865:Pilot Projects; D012512:Sarcoma, Ewing / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide
vernacular_title: Die GPO cooperativen Ewing-Sarkom Studien CESS 81/86: Bericht nach 6 1/2 Jahren.